Form EFFECT Spyre Therapeutics, Inc.
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 4, 2026 |
| Accession Number: | 0001628280-26-012785 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spyre Therapeutics Announces Grants of Inducement Awards
- GCL SI Showcases Scenario-Based PV Solutions at SNEC 2026, Driving Application-Specific Solar Deployment and Low-Carbon Development
- Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
